抗TIGIT抗体vibostolimab单药或联合帕博利珠单抗治疗晚期实体瘤(包括非小细胞肺癌)的首次人体1期研究
这项首次人体1期研究(NCT02964013;MK-7684-001)评估抗TIGIT抗体vibostolimab单药或联合帕博利珠单抗治疗晚期实体瘤及非小细胞肺癌的安全性和疗效。A部分入组76例晚期实体瘤患者,B部分入组抗PD-1/PD-L1初治或难治性NSCLC患者。vibostolimab联合帕博利珠单抗耐受良好,并在晚期实体瘤(包括晚期NSCLC)中显示出抗肿瘤活性。
要点
- A部分未报告剂量限制性毒性,单药和联合治疗最常见的治疗相关不良事件分别为疲乏和瘙痒。
- 抗PD-1/PD-L1初治NSCLC患者接受联合治疗确认ORR为26%,PD-L1阳性和阴性肿瘤均见缓解。
- 抗PD-1/PD-L1难治性NSCLC患者单药和联合治疗确认ORR均为3%。
核心结论
- vibostolimab联合帕博利珠单抗耐受良好,并在晚期实体瘤(包括晚期NSCLC)患者中显示出抗肿瘤活性。
研究设计与样本
- 首次人体1期研究(NCT02964013;MK-7684-001),A部分入组晚期实体瘤患者,B部分入组非小细胞肺癌(NSCLC)患者。
- A部分患者接受vibostolimab 2.1-700 mg单药或联合帕博利珠单抗200 mg;B部分患者接受vibostolimab 200 mg单药或联合帕博利珠单抗200 mg。
- 主要终点为安全性和耐受性;次要终点包括药代动力学和按RECIST v1.1评估的客观缓解率(ORR)。
主要发现
- A部分入组76例患者(单药34例;联合治疗42例),未报告剂量限制性毒性。
- A部分单药治疗56%和联合治疗62%的患者发生治疗相关不良事件(TRAE);3-4级TRAE分别发生于9%和17%的患者。
- A部分单药最常见TRAE为疲乏(15%)和瘙痒(15%),联合治疗最常见为瘙痒(17%)和皮疹(14%);确认ORR单药为0%,联合治疗为7%。
- B部分抗PD-1/PD-L1初治NSCLC患者39例(均接受联合治疗),85%发生TRAE,最常见为瘙痒(38%)和低白蛋白血症(31%),确认ORR为26%,PD-L1阳性和阴性肿瘤均见缓解。
- B部分抗PD-1/PD-L1难治性NSCLC患者67例(单药34例;联合治疗33例),单药56%和联合治疗70%发生TRAE,单药最常见为皮疹和疲乏(各21%),联合治疗最常见为瘙痒(36%)和疲乏(24%);确认ORR单药为3%,联合治疗为3%。
关键数值与推荐
- A部分vibostolimab单药剂量范围2.1-700 mg,联合帕博利珠单抗200 mg;B部分vibostolimab 200 mg单药或联合帕博利珠单抗200 mg。
- A部分确认ORR:单药0%,联合治疗7%。
- B部分抗PD-1/PD-L1初治NSCLC确认ORR为26%。
- B部分抗PD-1/PD-L1难治性NSCLC确认ORR:单药3%,联合治疗3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this first-in-human phase 1 study (NCT02964013; MK-7684-001), we investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM domain) antibody vibostolimab as monotherapy or in combination with pembrolizumab. PATIENTS AND METHODS: Part A enrolled patients with advanced solid tumors, and part B enrolled patients with non-small-cell lung cancer (NSCLC). Patients received vibostolimab 2.1-700 mg alone or with pembrolizumab 200 mg in part A and vibostolimab 200 mg alone or with pembrolizumab 200 mg in part B. Primary endpoints were safety and tolerability. Secondary endpoints included pharmacokinetics and objective response rate (ORR) per RECIST v1.1. RESULTS: Part A enrolled 76 patients (monotherapy, 34; combination therapy, 42). No dose-limiting toxicities were reported. Across doses, 56% of patients receiving monotherapy and 62% receiving combination therapy had treatment-related adverse events (TRAEs); grade 3-4 TRAEs occurred in 9% and 17% of patients, respectively. The most common TRAEs were fatigue (15%) and pruritus (15%) with monotherapy and pruritus (17%) and rash (14%) with combination therapy. Confirmed ORR was 0% with monotherapy and 7% with combination therapy. In part B, 39 patients had anti-PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1)-naive NSCLC (all received combination therapy), and 67 had anti-PD-1/PD-L1-refractory NSCLC (monotherapy, 34; combination therapy, 33). In patients with anti-PD-1/PD-L1-naive NSCLC: 85% had TRAEs-the most common were pruritus (38%) and hypoalbuminemia (31%); confirmed ORR was 26%, with responses occurring in both PD-L1-positive and PD-L1-negative tumors. In patients with anti-PD-1/PD-L1-refractory NSCLC: 56% receiving monotherapy and 70% receiving combination therapy had TRAEs-the most common were rash and fatigue (21% each) with monotherapy and pruritus (36%) and fatigue (24%) with combination therapy; confirmed ORR was 3% with monotherapy and 3% with combination therapy. CONCLUSIONS: Vibostolimab plus pembrolizumab was well tolerated and demonstrated antitumor activity in patients with advanced solid tumors, including patients with advanced NSCLC.
引用
- Niu J, Maurice-Dror C, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2021. PMID: 34800678. doi:10.1016/j.annonc.2021.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。